Hypothyroidism and hyperthyroidism are reported relatively less frequently in CTLA-4 inhibitors compared with PD-1/PD-L1 inhibitors, which was consistent with the findings of a previous study (67). This evidence concerns the gene PDCD1 and hyperthyroidism.